ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD)

PAD, characterized by vascular inflammation and associated calcification, affects 8.5 million people in the United States and contributes to more than 50,000 limb amputations annually, yet there are... | June 20, 2023

Related Keywords

United States ,American ,Stephenc Glover ,Dave Schemelia ,Casey Mcdonald ,Nasdaq ,Securities Exchange ,Zyversa Therapeutics Inc ,Journal Of The American Heart Association ,Versa Therapeutics ,American Heart Association ,Peripheral Arterial Disease ,Zyversa Therapeutics ,Cholesterol Efflux Mediator ,Securities Exchange Act ,Private Securities Litigation Reform Act ,